» Articles » PMID: 34350117

Development and Validation of a Nomogram and a Comprehensive Prognostic Analysis of an LncRNA-Associated Competitive Endogenous RNA Network Based on Immune-Related Genes for Locally Advanced Rectal Cancer With Neoadjuvant Therapy

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Aug 5
PMID 34350117
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is a common digestive tract tumor worldwide. In recent years, neoadjuvant chemoradiotherapy (CRT) has been the most comprehensive treatment for locally advanced rectal cancer (LARC). In this study, we explored immune infiltration in rectal cancer (RC) and identified immune-related differentially expressed genes (IRDEGs). Then, we identified response markers in datasets in GEO databases by principal component analysis (PCA). We also utilized three GEO datasets to identify the up- and downregulated response-related genes simultaneously and then identified genes shared between the PCA markers and three GEO datasets. Based on the hub IRDEGs, we identified target mRNAs and constructed a ceRNA network. Based on the ceRNA network, we explored prognostic biomarkers to develop a prognostic model for RC through Cox regression. We utilized the specimen to validate the expression of the two biomarkers. We also utilized LASSO regression to screen hub IRDEGs and built a nomogram to predict the response of LARC patients to CRT. All of the results show that the nomogram and prognostic model offer good prognostic value and that the ceRNA network can effectively highlight the regulatory relationship. hsa-mir-107 and WDFY3-AS2 may be prognostic biomarkers for RC.

Citing Articles

The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro study.

Deli H, Vakili-Ghartavol Z, Asgari Y, Tavoosidana G, Eftekhar E, Ghahremani M BMC Cancer. 2025; 25(1):46.

PMID: 39789474 PMC: 11715296. DOI: 10.1186/s12885-024-13392-2.


Neoadjuvant treatment of rectal cancer: Where we are and where we are going.

Portillo E, Counago F, Lopez-Campos F World J Clin Oncol. 2024; 15(7):790-795.

PMID: 39071468 PMC: 11271721. DOI: 10.5306/wjco.v15.i7.790.


Validated Pretreatment Prediction Models for Response to Neoadjuvant Therapy in Patients with Rectal Cancer: A Systematic Review and Critical Appraisal.

Tanaka M, Geubels B, Grotenhuis B, Marijnen C, Peters F, Van der Mierden S Cancers (Basel). 2023; 15(15).

PMID: 37568760 PMC: 10417363. DOI: 10.3390/cancers15153945.


MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review.

Yang I, Yip K, Chang Y, Chen Y, Huang C, Tsai H Cancers (Basel). 2023; 15(5).

PMID: 36900159 PMC: 10000071. DOI: 10.3390/cancers15051358.

References
1.
Zhang C, Zheng J, Lin Z, Lv H, Ye Z, Chen Y . Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma. Aging (Albany NY). 2020; 12(4):3486-3501. PMC: 7066877. DOI: 10.18632/aging.102824. View

2.
Mima K, Sukawa Y, Nishihara R, Qian Z, Yamauchi M, Inamura K . Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol. 2015; 1(5):653-61. PMC: 4537376. DOI: 10.1001/jamaoncol.2015.1377. View

3.
Li W, Ma S, Bai X, Pan W, Ai L, Tan W . Long noncoding RNA WDFY3-AS2 suppresses tumor progression by acting as a competing endogenous RNA of microRNA-18a in ovarian cancer. J Cell Physiol. 2019; 235(2):1141-1154. DOI: 10.1002/jcp.29028. View

4.
Konishi T, Matsukuma S, Fuji H, Nakamura D, Satou N, Okano K . Principal Component Analysis applied directly to Sequence Matrix. Sci Rep. 2019; 9(1):19297. PMC: 6917774. DOI: 10.1038/s41598-019-55253-0. View

5.
Tendulkar R, Agrawal S, Gao T, Efstathiou J, Pisansky T, Michalski J . Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016; 34(30):3648-3654. DOI: 10.1200/JCO.2016.67.9647. View